The Los Angeles Post
California & Local U.S. World Business Lifestyle
Today: January 15, 2025
Today: January 15, 2025

California Gov. Gavin Newsom vetoes bill aimed at limiting the price of insulin

California Insulin Veto
October 08, 2023

SACRAMENTO, Calif. (AP) — Gov. Gavin Newsom has vetoed a bill that would have stopped insurance companies from charging more than $35 for insulin.

The bill would have banned health plans and disability insurance policies from imposing any out-of-pocket expenses on insulin prescription drugs above $35 for a 30-day supply. That would have included deductibles and co-pays.

Newsom, a Democrat, said earlier this year that California would soon start making its own brand of insulin. The state has a $50 million contract with the nonprofit pharmaceutical company Civica Rx to manufacture the insulin under the brand CalRx. The state would sell a 10 milliliter vial of insulin for $30.

“With CalRx, we are getting at the underlying cost, which is the true sustainable solution to high-cost pharmaceuticals,” Newsom wrote in a message explaining why he vetoed the bill on Saturday. “With copay caps however, the long-term costs are still passed down to consumers through higher premiums from health plans.”

State Sen. Scott Wiener, a Democrat from San Francisco who crafted the bill, called Newsom's veto “a major setback that will keep tens of thousands of diabetic Californians trapped in the terrible choice between buying insulin and buying food.”

“This is a missed opportunity that will force them to wait months or years for relief from the skyrocketing costs of medical care when they could have had it immediately,” Wiener said in a news release.

Insulin is a hormone produced by the pancreas that converts sugar into energy. People who have diabetes don't produce enough insulin. People with Type 1 diabetes must take insulin every day to survive.

In January, California Attorney General Rob Bonta sued the companies that make and promote most of the nation's insulin, accusing them of colluding to illegally increase the price.

In March, the largest insulin makers announced they would voluntarily reduce the price of their products.

Related

Business|Economy|Europe|Finance|Political

UK stagflation risk adds pressure on Reeves after market volatility

British inflation figures will be closely watched on Wednesday as a sharp jump in government borrowing costs, concerns about domestic and global price pressures and

UK stagflation risk adds pressure on Reeves after market volatility
Americas|Business|Economy|Political

Canada clears $34 billion Bunge-Viterra merger with conditions

Canada on Tuesday approved with conditions U.S. grains merchant Bunge's $34 billion merger with Glencore-backed Viterra, clearing one of the final remaining

Canada clears $34 billion Bunge-Viterra merger with conditions
Business|Economy|Education|Political|Sports

NCAA to dole out $1.2B to help pay for House settlement. Its president asks for Congress to step in

Stressing his own organization’s ability to pay out $1.2 billion over 10 years to help settle an industry-changing lawsuit, NCAA President Charlie Baker also urged Congress to pass legislation that could put college sports on a better path

NCAA to dole out $1.2B to help pay for House settlement. Its president asks for Congress to step in
Business|Economy|Health|Political|US

FTC finds middlemen inflate specialty generic drug prices by billions of dollars

FTC finds middlemen inflate specialty generic drug prices by billions of dollars

FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Share This

Popular

Business|Economy|Europe|Finance

Euro zone households could increase consumption, ECB chief economist says

Euro zone households could increase consumption, ECB chief economist says
Asia|Business|Economy|Finance|Political|Stock Markets

Foreigners sold South Korean equities last month by most since early 2020

Foreigners sold South Korean equities last month by most since early 2020
Asia|Business|Economy|Finance|Political

Japan likely to miss primary budget surplus target for FY2025, sources say

Japan likely to miss primary budget surplus target for FY2025, sources say
Asia|Business|Economy|Finance|Stock Markets

Oil little changed as falling US stockpiles outweigh soft demand outlook

Oil little changed as falling US stockpiles outweigh soft demand outlook